Research Analysts Offer Predictions for ETON Q1 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Eton Pharmaceuticals in a research note issued on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.20 for the quarter, down from their prior forecast of $0.23. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2027 earnings at $1.95 EPS and FY2030 earnings at $4.42 EPS.

Other equities analysts also recently issued research reports about the stock. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen cut shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Finally, Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $31.00.

Eton Pharmaceuticals Trading Up 0.5%

NASDAQ:ETON opened at $17.53 on Wednesday. The firm has a market capitalization of $470.15 million, a P/E ratio of -70.12 and a beta of 1.19. The business has a 50 day simple moving average of $16.23 and a 200 day simple moving average of $17.24. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.63 and a quick ratio of 1.25. Eton Pharmaceuticals has a 12-month low of $11.09 and a 12-month high of $23.00.

Institutional Trading of Eton Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Opaleye Management Inc. grew its holdings in Eton Pharmaceuticals by 0.3% during the second quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after acquiring an additional 7,930 shares during the period. EcoR1 Capital LLC boosted its position in shares of Eton Pharmaceuticals by 2.0% during the 2nd quarter. EcoR1 Capital LLC now owns 2,030,544 shares of the company’s stock valued at $28,935,000 after purchasing an additional 40,756 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after purchasing an additional 31,942 shares during the last quarter. Geode Capital Management LLC lifted its stake in Eton Pharmaceuticals by 98.8% during the second quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after purchasing an additional 294,617 shares during the last quarter. Finally, State Street Corp boosted its holdings in Eton Pharmaceuticals by 14.5% during the fourth quarter. State Street Corp now owns 501,925 shares of the company’s stock worth $8,488,000 after buying an additional 63,480 shares in the last quarter. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.